- Title
- Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
- Creator
- Hasnain, MG; Nath, P; Maruf, S; Nabi, SG; Hossain, AFMA; Ahmed, B-N; Mondal, D; Basher, A
- Relation
- BMC Research Notes Vol. 11, no. 918
- Publisher Link
- http://dx.doi.org/10.1186/s13104-018-4036-8
- Publisher
- BioMed Central
- Resource Type
- journal article
- Date
- 2018
- Description
- Objective: Based on studies in India (as there was no studies from outside India) amphotericin B deoxycholate has been considered as a backup drug for treatment of visceral leishmaniasis. However, treatment response and adverse effect to anti-leishmanial drugs may vary across different populations and in Bangladesh the effect to amphotericin B deoxycholate for treatment of visceral leishmaniasis is still unknown. Therefore, there is a need to explore cure rate and adverse effects to amphotericin B deoxycholate to justify its use on visceral leishmaniasis patients in Bangladesh. Result: Here we report 34 visceral leishmaniasis patients who received treatment with amphotericin B deoxycholate in the Surya Kanta Kala-azar Research Centre from December 2011 to June 2015. The dose of the treatment was 1 mg/kg body weight for 15 days followed up until 12 months after treatment. Response to amphotericin B deoxycholate treatment was excellent as all 34 patients achieved a final cure. Hypokalaemia (47%), shivering (47%), vomiting (35%) and acidity (15%) were most common adverse events. However, we did not observe any serious adverse events. Amphotericin B deoxycholate for relapse visceral leishmaniasis was found to be highly effective and safe. Our study justified to include amphotericin B deoxycholate as a second line drug for visceral leishmaniasis in Bangladesh.
- Subject
- treatment outcome; visceral leishmaniasis; amphotericin B deoxycholate; Bangladesh
- Identifier
- http://hdl.handle.net/1959.13/1408862
- Identifier
- uon:35895
- Identifier
- ISSN:1756-0500
- Rights
- © The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Language
- eng
- Full Text
- Reviewed
- Hits: 5579
- Visitors: 5874
- Downloads: 303
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT02 | Publisher version (open access) | 981 KB | Adobe Acrobat PDF | View Details Download |